



ASX / Media Release
22 March 2024

Invex Therapeutics Ltd (Invex, ASX:IXC, or the Company) a biopharmaceutical company focused on the development and commercialisation of Presendin™ for neurological conditions relating to raised intracranial pressure today advises an amendment in relation to the Appendix 3.4A lodged on 1 November 2023.

The Company confirms a change to option pricing as a result of the return of capital being approved by shareholders on 5 December 2023. The exercise price of the outstanding unlisted options on issue has been reduced by \$0.19 per share.

The Company confirms it has the following unlisted options on issue.

400,000 unlisted options expiring 8 April 2024 at an exercise price of \$0.91.

1,160,000 unlisted options expiring 1 December 2026 at an exercise price of \$0.68.

- ENDS -

This release dated 22 March 2024 has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics.

For more information, please contact:

Company/Investors

Dr Thomas Duthy
Executive Director
tduthy@invextherapeutics.com
+61 402 493 727

Media

Margie Livingston
Ignite Communications
margie@ignitecommunications.com.au
+61 438 661 131

To subscribe to Invex email alerts, please visit www.invextherapeutics.com and follow us on Twitter **@InvexThera_ASX**

About Invex Therapeutics Ltd

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin™. www.invextherapeutics.com.